Abstract:Purpose: Modulation of the BMP pathway remains an attractive target for development of novel anabolic treatments for osteoarthritis. We are aiming to identify chondro-specific small molecule enhancers of the BMP pathway. The ideal compound promotes the anabolic potential of the chondrocytes without pushing the cells into hypertrophy and does not induce/enhance TGFb-driven tumor formation/metastasis. We used a “chemical biology approach” whereby 25K compounds were screened in a BMP reporter cell-line for their enhancing activity. Next, we applied “phenotypic filter assays” to identify compounds with the desired profile. Like this, we take full advantage of the diversity available in the chemical library and maximize our chances to come up with innovative modulators of BMP pathway possessing tissue selective capacities and no/minor side effects. Methods: 25K compounds were screened in a BMP reporter cell line for their BMP enhancing potential at 10μM (%PAC > 68%). Cytotoxic and general enhancers have been removed (NFkB counterscreen). Commercially available hit-analogues were ordered, evaluated in the BMP reporter (hit explosion) and in primary human adult articular chondrocytes in alginate bead culture system at 10μM to select promising series. The effect on aggrecan production was evaluated in the interterritorial matrix of the beads using a commercially available ELISA and gene expression profile was studied on the cell pellet using qRT-PCR (COL2, ACAN, SOX9, MIA, COL1, BGLAP). Medicinal chemistry efforts produced > 300 derivatives of promising series. Potency was evaluated as previously described and used to identify SAR of the series. In addition, tissue selectivity (osteogenic differentiation assay, TGFb-driven tumor formation in lung fibroblasts and breast cancer cell invasion model) and pathway specificity (TGFb reporter/NFkB (TNF) reporter) were performed to eliminate series/compounds showing unselective/aspecific side effects. Results: From the 25K compounds, hits belonging to 12 chemical series were identified showing > 68% enhancement in the BMP reporter, showing no toxicity in hepG2 cells nor general transcriptional activation. Hit explosion confirmed the initial results and provided basic SAR. Using primary human chondrocytes the most promising series showed a concentration-dependent increase of aggrecan production; COL2, ACAN and MIA upregulation; no effect on hypertrophy-associated genes. The selected series are pathway specific (no TGFb enhancement - no TNF enhancement), tissue selective (no enhancement of osteogenic differentiation) and enhance/induce no TGFb-driven tumor formation/metastasis. Following hit to lead optimization, SAR has been refined and potency (EC50) already improved to sub-micromolar range. Conclusions: Using this chemical biological approach we identified novel series showing pro-anabolic properties in the articular cartilage, tissue selectivity and pathway specificity, with no to minimal side effects (toxicity, TGFb-driven tumor formation/metastasis) and a clear structure activity relationship. Further in vitro and in vivo activity testing is ongoing and results are expected soon.

Design, synthesis and biological evaluation of novel pyrimidine derivatives as bone anabolic agents promoting osteogenesis via the BMP2/SMAD1 signaling pathway

Synthesis and Evaluation of a Novel Series of Diphenylamine and Diphenylether Derivatives with Osteoblastogenic and Osteogenic Effects via CDK8 Inhibition

Discovery of a novel class of benzimidazoles as highly effective agonists of bone morphogenetic protein (BMP) receptor signaling

BMP2–ERK–ATF4 Axis-Based 6-methoxybenzofuran Compound I-9 Acts as Candidate Drug for Bone Formation and Anti-Osteoporosis

A Novel Osteogenic Oxysterol Compound for Therapeutic Development to Promote Bone Growth: Activation of Hedgehog Signaling and Osteogenesis Through Smoothened Binding

Therapeutic potential of phosphodiesterase inhibitors in the treatment of osteoporosis: Scopes for therapeutic repurposing and discovery of new oral osteoanabolic drugs

Synthesis and evaluation of 2-NMPA derivatives as potential agents for prevention of osteoporosis in vitro and in vivo

Synthesis and Biological Evaluation of Novel Piperidine-3-Carboxamide Derivatives as Anti-Osteoporosis Agents Targeting Cathepsin K

Selective Small Molecule Compounds Increase BMP-2 Responsiveness by Inhibiting Smurf1-mediated Smad1/5 Degradation

Design, synthesis and anti-osteosarcoma activity study of novel pyrido[2,3-d]pyrimidine derivatives by inhibiting DKK1-Wnt/β-catenin pathway

Synthesis of N-methylpyridine-chlorofuranformamide analogs as novel OPG up-regulators and inhibitors of RANKL-induced osteoclastogenesis

Design, Synthesis, and Biological Evaluation of β-Trifluoroethoxydimethyl Selenides as Potent Antiosteoporosis Agents

Synthesis of Heterocyclic Ring-Fused Bisnoralcohol Derivatives as Novel Small-Molecule Antiosteoporosis Agents

Computational prediction of small molecules with predicted binding to FGFR3 and testing biological effects in bone cells

Novel Indolyl-Benzimidazole Compounds Promote in vitro Wound Healing and Osteogenic Differentiation of Pluripotent Cells

Development of an Orally Active Small-Molecule Inhibitor of Receptor Activator of Nuclear Factor-κB Ligand

A Process for the Design and Development of Novel Bone Morphogenetic Protein-7 (BMP-7) Mimetics With an Example: THR-184

Design, synthesis and evaluation of a pyrazolo[3,4-d]pyrimidine derivative as a novel and potent TGFβ1R1 inhibitor

Design, Synthesis and Biological Evaluation of Novel Dithiocarbamate-Substituted Diphenylaminopyrimidine Derivatives As BTK Inhibitors

Enhancing Osteogenic Potential: Controlled Release of Dopamine D1 Receptor Agonist SKF38393 Compared to Free Administration

Identification of Enhancers of BMP Signaling Pathway with Cartilage Anabolic Properties